Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC et al.

I'll research this case thoroughly before drafting the overview.

Good foundation. Now let me dig into the MDL, the IPRs, and the outcome.

Let me verify the MDL resolution, IPR outcomes, and market context.

Case Overview and Background

Parties and their roles. This is a branded-vs.-generic Hatch-Waxman action, not an NPE/PAE assertion. Plaintiff Merck Sharp & Dohme Corp. — the New Jersey-incorporated Merck & Co., Inc. subsidiary with principal offices at One Merck Drive, Whitehouse Station, NJ (Compl., D.I. 1) — is the NDA holder and Orange Book patentee for Januvia (sitagliptin phosphate), Janumet (sitagliptin + metformin HCl), and Janumet XR (extended-release sitagliptin + metformin) (MDL No. 2902 transfer order, J.P.M.L., July 2019). Defendants are the Alvogen group's generic arms: Alvogen Pine Brook LLC (f/k/a Alvogen Pine Brook, Inc.), a Delaware LLC with offices in Pine Brook, NJ; Alvogen Malta Operations Ltd. (Malta); and Alvogen Luxembourg / Alvogen Lux Holdings S.à r.l. (Answer & Countercls., paragraphfour.com archive of DED 19-cv-310). Alvogen Pine Brook and Alvogen Malta answered jointly, denied infringement, affirmatively pleaded invalidity under §§ 101, 102, 103, 112 and obviousness-type double patenting, and counterclaimed for declaratory judgment of non-infringement/invalidity. (Alvogen Luxembourg appears in the complaint and docket but not in the eventual consent judgment; I would flag that as not fully sourced rather than assert its disposition.)

Accused product and technology. The accused conduct is Alvogen's submission of ANDA No. 205341 with a Paragraph IV certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV), seeking FDA approval to market generic sitagliptin phosphate/metformin HCl extended-release tablets — i.e., a generic of Janumet XR — in 50/500 mg, 50/1000 mg, and 100/1000 mg strengths, before the '708 patent's expiration (Compl. ¶¶ 34–35; paragraphfour.com docket summary, which notes the Alvogen and Anchen/Par cases involved only Janumet XR). Merck alleged infringement under 35 U.S.C. § 271(e)(2) and, alternatively, sought a declaratory judgment of infringement.

Patent asserted. Only U.S. Patent No. 7,326,708, "Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor," issued February 5, 2008, inventors Cypes, Chen, Ferlita, Hansen, Lee, Vydra, and Wenslow (Compl. ¶¶ 28–30). Technically, the '708 patent claims the dihydrogenphosphate (DHP) salt of sitagliptin at a 1:1 phosphate-anion:sitagliptin stoichiometry (claim 1), the (R)-configuration salt (claim 2), the (S)-enantiomer (claim 3), the crystalline monohydrate of the 1:1 DHP salt (claim 4), and processes for preparing the crystalline monohydrate from isopropanol/water (claim 24) (see In re Sitagliptin Phosphate ('708 & '921) Patent Litig., Markman Op., Nov. 17, 2020, D.I. 193). It is listed in the Orange Book for Januvia, Janumet, and Janumet XR, with a nominal expiration of November 24, 2026 (plus pediatric exclusivity; DrugPatentWatch).

Procedural posture and venue. Filed February 13, 2019 in the U.S. District Court for the District of Delaware and assigned to Judge Richard G. Andrews (C.A. No. 1:19-cv-00310-RGA). By J.P.M.L. transfer order in July 2019, this case and thirteen companion suits against other generics (Anchen, Sandoz, Apotex, Zydus, Macleods, Par, Sun, Lupin, Teva, Torrent, and others) — totaling 26 ANDAs — were centralized as In re Sitagliptin Phosphate ('708 & '921) Patent Litigation, MDL No. 19-2902-RGA (D. Del.), with a consolidated Markman and coordinated pretrial proceedings. Venue mattered: thirteen of the fourteen actions were already in Delaware, the J.P.M.L. expressly selected Delaware as transferee for "efficient resolution" given "the potential entry of generic diabetes drugs into the market," and Alvogen Pine Brook consented to jurisdiction as a Delaware LLC, which mooted a parallel New Jersey declaratory-judgment suit (Merck 10-Q disclosure). Delaware is also the preeminent Hatch-Waxman forum, and Judge Andrews was chosen for his patent experience.

Outcome and why the case matters. This action did not go to trial. A consent judgment was entered in July 2020 (docketed July 16, 2020; text signed "this day of July, 2020") under which Alvogen, its affiliates, successors, and assigns are enjoined from making, using, selling, offering for sale, importing, or distributing the ANDA No. 205341 product, and all claims, counterclaims, affirmative defenses, and demands were dismissed with prejudice without costs or fees (Consent Judgment, MDL 19-2902-RGA / C.A. 19-310-RGA, archived at paragraphfour.com). Alvogen was one of roughly two dozen generics that settled with Merck in this MDL; as part of the settlement architecture, generics obtained early-entry rights, with Alvogen's Janumet XR product reportedly licensed for launch around July 2026 (Merck 2021 Form 10-Q; note that some third-party trackers state May 2026 for Januvia/Janumet and July 2026 for Janumet XR, and one source states May 2027 — the dates are inconsistently reported, so treat the precise entry date as unsettled).

The case is notable less for its own ruling than for its role in the IPR linkage and the sitagliptin patent-cliff story. Mylan led the attack on the '708 patent in IPR2020-00040, filed October 30, 2019, instituted May 12, 2020 over claims 1–4, 17, 19, and 21–23; Dr. Reddy's (IPR2020-01060) and Sun (IPR2020-01072) joined, and the Board issued a final written decision on May 7, 2021 holding no challenged claims unpatentable (Mylan's anticipation theory based on the Edmondson/WO '498 reference failed on express and inherent disclosure grounds; obviousness failed, in part because Merck antedated the reference and the parties jointly owned it). The Federal Circuit affirmed on September 29, 2022 (Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp., No. 21-2121, addressing the In re Petering "at once envisage" doctrine — the "957 salts" analysis — and substantial-evidence review). The '708 patent was also upheld after a five-day bench trial in the parallel N.D. W. Va. case, Merck Sharp & Dohme LLC v. Mylan Pharmaceuticals Inc., No. 1:19-cv-00101 (Judge Keeley, Oct. 26, 2022). The IPR institution decision is itself frequently cited in discretionary-denial discussions, as the Board took supplemental briefing on the Apple v. Fintiv factors and declined to deny institution. Commercially, the stakes were large: Januvia/Janumet were among Merck's top-selling products, with roughly $5.3 billion in combined 2021 sales (FiercePharma), and the '708 salt/polymorph patent was the last meaningful U.S. barrier to generic sitagliptin, prompting ~21+ settlements and this MDL. Caveat: Because the '708 patent's asserted claims are limited to the DHP salt and its monohydrate, at least one generic (Zydus's Zituvio) has been able to market sitagliptin free base — a formulation not covered by the '708 claims — which is a useful reminder that this patent, though durable, is narrow in scope.

I'll research this case systematically across the docket, PTAB, and legal press.

Good foundation. Let me dig into docket details, MDL consolidation, and IPR outcomes.

Let me get the Alvogen-specific docket and the claim construction opinion.

Key Legal Developments — Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC, No. 1:19-cv-00310-RGA (D. Del.)

Bottom line: This was one of 14 parallel Hatch-Waxman suits Merck filed on the same day against generic sitagliptin-phosphate ANDA filers. The Alvogen action was folded into MDL No. 2902 but never reached Markman, trial, or judgment on the merits — it ended in a negotiated consent judgment and injunction in July 2020, roughly 17 months after filing. The invalidity fight over the '708 patent was litigated to a final written decision at the PTAB in the parallel Mylan IPR, where Merck prevailed.

---

1. Filing & Initial Pleadings

The complaint (text; full complaint source) asserted U.S. Patent No. 7,326,708 ("Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor," issued 2008-02-05, Orange Book expiry 2026-11-24 with pediatric exclusivity to 2027-05-24), covering the sitagliptin phosphate in JANUMET XR®. Alvogen's ANDA No. 205341 carried a Paragraph IV certification. Notably, Merck pleaded that "Alvogen did not contest infringement of claim 1 of the '708 patent" in its notice letter — so infringement was effectively a non-issue and validity carried the case. Count I was § 271(e)(2)(A) infringement; Count II was a declaratory judgment of infringement. The Alvogen case involved only the '708 patent (not the companion '921 patent, U.S. 8,414,921, which Merck asserted against only some of the MDL defendant groups).

Answer, affirmative defenses, and counterclaims (source): Alvogen pleaded three affirmative defenses — (1) invalidity under §§ 101, 102, 103, 112, equitable defenses, and obviousness-type double patenting; (2)(3) non-infringement under §§ 271(a)–(c) and § 271(e). Its counterclaims sought declaratory judgments of non-infringement and invalidity of the '708 patent under the Declaratory Judgment Act and 35 U.S.C. § 271(e)(5). (The answer document itself does not bear a legible filing date in the copy I retrieved; the operative deadline was 2019-04-17.)

Counsel: Merck — Williams & Connolly LLP (Bruce R. Genderson, Jessamyn S. Berniker, Stanley E. Fisher, Alexander S. Zolan, Elise M. Baumgarten, Shaun P. Mahaffy, Anthony H. Sheh, Jingyuan Luo) with Delaware counsel Morris, Nichols, Arsht & Tunnell (Michael P. Kelly, Daniel M. Silver, Alexandra M. Joyce). Alvogen — Delaware counsel Kelly E. Farnan (Richards, Layton & Finger) (UniCourt party/counsel record).

---

2. MDL Consolidation (the single most consequential pretrial development)

• At the time of Merck's JPML motion, thirteen actions were pending in D. Del. and one in N.D. W. Va. (Mylan), with the '708 patent asserted against 23 defendants in 13 groups and the '921 patent against 3 groups (Merck's § 1407 motion).
• 2019-08-08: JPML issues the § 1407 transfer order in In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation, MDL No. 2902, centralizing pretrial proceedings before Judge Andrews in D. Del. The Alvogen case (1:19-cv-00310) is listed on Schedule A (JPML Transfer Order; CourtListener Doc. 56). The panel cited the need to prevent inconsistent claim construction and validity rulings.
• 2019-08-08/09: MDL master docket 1:19-md-02902-RGA opened; the Alvogen action became an "associated case." Docket entries in the Alvogen case begin to be filed on both dockets (see the MDL docket reproduced at PACER excerpt).

Motions to dismiss / transfer / stay: I found no motion to dismiss for lack of venue or motion to transfer filed by Alvogen (venue was solid: Alvogen Pine Brook is a Delaware LLC). The only venue challenge in the MDL came from Mylan, which moved to dismiss Merck's Delaware action and prompted Merck to voluntarily dismiss and refile in N.D. W. Va. No motion to stay the Alvogen case pending IPR was filed — Alvogen settled before the lead IPR was even instituted (see §§ 4–5 below).

---

3. Discovery Milestones and Claim Construction

Discovery (MDL-wide, per Merck's filings in IPR2020-00040):

• Substantial completion of document production was due 2020-04-22. Merck had produced ~2 million pages; Mylan ~20,000 pages; other defendants ~700,000 pages (Merck's Fintiv supplemental brief).
• Fact discovery ran through Fall 2020; opening expert reports were due January 2021 (Merck preliminary response, IPR2020-01060).
• A discovery-dispute conference transcript dispute involving third-party Biocon (source of sitagliptin API) generated two memorandum orders in October 2020 (D.I. 237, 239, 258), the second granting modest redactions (MDL D.I. 107, 2020-10-21) (memorandum order).
• Strategically, Merck emphasized that no MDL defendant had stipulated to infringement of the '708 patent — a point it used to argue the parallel IPR would not resolve the MDL.

Claim construction: Markman activity was MDL-level, not Alvogen-level. On the MDL schedule, Merck filed its opening claim-construction brief 2020-03-20; defendants' brief was due 2020-05-01; and

I'll research the counsel of record for Merck in this case.

I have strong leads. Let me confirm the specific docket entries for C.A. No. 19-310 and any later appearances/withdrawals.

Let me confirm the consent judgment signature block and check for any later counsel changes.

Counsel of Record for Plaintiff Merck Sharp & Dohme Corp. — Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC, C.A. No. 1:19-cv-00310-RGA (D. Del.)

Sourcing note up front. Merck's appearances in this docket are documented in the signature blocks of the Complaint (D.I. 1, filed Feb. 13, 2019) and Answer/Counterclaims (D.I. 2, filed Apr. 17, 2019), reproduced in the paragraphfour.com case archive, in the pro hac vice admission entries on the 19-310 docket (D.I. 6, Mar. 2019), and in the MDL/IPR filings. This case settled by consent judgment on July 16, 2020 (D.I. 127), so the roster below is fixed as of mid-2020 — I found no notices of withdrawal of Merck counsel, which is consistent with the case being resolved rather than tried. I did not find any Merck in-house attorney entering an appearance of record in 19-310; if one did, it is not reflected in the sources I could retrieve, and I will not invent one.

---

1. Local counsel — McCarter & English, LLP (Wilmington, Delaware)

Merck's Delaware bar members of record, all signing the Complaint at D.I. 1. Local counsel in D. Del. must be the CM/ECF filers of record (L.R. 83.5(d)), so this firm handled all docket filings for Merck.

Address of record: Renaissance Centre, 405 N. King Street, 8th Floor, Wilmington, DE 19801, (302) 984-6300 (mkelly@mccarter.com, dsilver@mccarter.com, ajoyce@mccarter.com).

---

2. Lead (out-of-state) trial counsel — Williams & Connolly LLP, Washington, D.C.

Merck's principal merits and trial team, admitted pro hac vice in 19-310 (D.I. 6 covered Genderson, Berniker, and Fisher; PHV entries for Luo and Sheh appear on the docket Mar. 7–8, 2019). All W&C attorneys listed here signed the D.I. 1 Complaint.

Address of record: 725 Twelfth Street, N.W., Washington, DC 20005, (202) 434-5000.

---

3. Later MDL/IPR additions to the Merck team (flag: MDL-level, not confirmed on the 19-310 docket itself)

The consolidated MDL docket for 1:19-md-02902-RGA and Merck's IPR2020-00040 mandatory notices list two additional W&C attorneys appearing for Merck in the coordinated sitagliptin proceedings:

• Alexander S. Zolan — W&C (PHV); listed as backup counsel in IPR2020-00040 and as a Merck PHV attorney on the MDL docket; argued at the Markman hearing.
• Elise M. Baumgarten — W&C (PHV); backup counsel in IPR2020-00040 and on the MDL docket.

Caution: these two appear in the MDL lead-case and PTAB records. Because 19-310 settled in July 2020 and I could not retrieve a case-specific docket sheet for 19-310 confirming a separate appearance by them, I would not state as fact that they entered an appearance in 19-310 specifically.

---

Contradictions / gaps to flag

1. UniCourt's attorney list is incomplete. Its 19-310 page (last updated 7/11/2020) lists only five plaintiff attorneys (Jingyuan Luo, Anthony H. Sheh, Michael P. Kelly, Daniel M. Silver, Alexandra M. Joyce) and omits Genderson, Berniker, Fisher, and Mahaffy — likely an artifact of which PHV attorneys carried the CM/ECF "notice" flag. The D.I. 1 signature block, which is the authoritative source for who signed for Merck, lists all nine W&C/McCarter names above. Use the signature block, not the aggregator.
2. The MDL docket listing is a consolidated view. The "Merck Sharp & Dohme Corp. represented by…" list pulled from the MDL docket sheet also includes non-Delaware Merck counsel such as Frank X. Duff, James F. Companion, and Sandra K. Law of Schrader Byrd & Companion, PLLC (Wheeling, W. Va.) — these were Merck's local counsel in the parallel N.D. W. Va. Mylan action (C.A. 1:19-cv-00101-IMK), not 19-310 counsel. I would not attribute them to this case.
3. No in-house Merck appearance found. An IPR deposition transcript in IPR2020-00040 references additional W&C personnel (Sarah Uribe, David Krinsky) but that is PTAB-side, not a D. Del. appearance.
4. Alvogen side, for contrast: Defendants were represented by Kelly E. Farnan and Renée M. Mosley of Richards, Layton & Finger (Wilmington) as Delaware counsel, with Axinn, Veltrop & Harkrider LLP (Matthew J. Becker, Brett Garrison) as of counsel — per the Answer/Counterclaims (D.I. 2) archived at paragraphfour.com. (This is separate from Alvogen's Young Conaway/Proskauer team in the unrelated Pharmacyclics v. Alvogen matter, which should not be conflated with this case.)

Bottom line: The two-firm structure typical of D. Del. ANDA litigation — Williams & Connolly LLP (Washington, D.C.) as lead merits/trial counsel, with McCarter & English LLP (Wilmington) as Delaware local/lead-of-record counsel — applies here, with Genderson and Fisher as the senior leads and Michael P. Kelly as the designated lead local counsel of record.

I'll research defense counsel of record for the Alvogen entities in this case.

Good initial hits. Let me verify against the docket sheet and check for any additional pro hac vice counsel.

Let me confirm the pro hac vice admissions and check whether any other defense counsel appeared.

Defense Counsel of Record — Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC, C.A. No. 1:19-cv-00310-RGA (D. Del.)

Structure of the defense team

Alvogen used the classic two-tier Delaware Hatch-Waxman arrangement: a Delaware firm as counsel of record / lead counsel on the docket (required by D. Del. Local Rule 83.5(d) — only Delaware-bar registered users may file), and an out-of-state firm with the substantive patent expertise appearing "OF COUNSEL" and admitted pro hac vice.

• Richards, Layton & Finger, P.A. (Wilmington, DE) — Delaware counsel of record; docketed as LEAD ATTORNEY for both Alvogen defendants (D. Del. docket sheet, MDL No. 1:19-md-02902-RGA caption text, as reproduced in PTAB filings). Signed the Answer/Counterclaims, the extension stipulations, and the Consent Judgment.
• Axinn, Veltrop & Harkrider LLP (Hartford, CT and Washington, DC) — out-of-state counsel listed as "OF COUNSEL" on the Alvogen pleadings; admitted pro hac vice.

Individual attorneys

Sources for the above: the Answer and Counterclaims filed April 17, 2019 on behalf of Alvogen Pine Brook LLC and Alvogen Malta Operations Ltd. (archived at paragraphfour.com as dedc19cv0310A.pdf), which carries the RLF signature block and the Axinn "OF COUNSEL" block; the D. Del. docket-sheet party/attorney text for C.A. No. 1:19-cv-00310-RGA and MDL No. 1:19-md-02902-RGA (reproduced in PTAB filings in IPR2020-00040); the Consent Judgment (D.I. 127, entered July 16, 2020), signed "/s/ Renée Mosley Delcollo" with the Farnan and Delcollo bar numbers; and the UniCourt docket summary for 1:19-cv-00310, which lists Kelly E. Farnan as the sole "Defendant Attorney."

Relevant experience (one line each)

• Kelly E. Farnan — Heads Richards Layton's Intellectual Property Group; named Managing IP's 2025 Delaware Litigator of the Year and Chambers USA Band 1; a go-to Delaware trial counsel in Hatch-Waxman matters (e.g., Lundbeck v. Apotex, Pharmacyclics v. Alvogen Pine Brook) and in Judge Andrews' courtroom. (rlf.com firm announcement, Apr. 25, 2025.)
• Renée M. Mosley (Delcollo) — RLF Delaware litigator; served as Delaware counsel of record on this Alvogen matter, handling the answer, counterclaims, and settlement papering. (Verified only from the filings above; I found no independent firm bio confirming her current practice.)
• Matthew J. Becker — Chair of Axinn's IP practice, 25+ years and 100+ patent litigations, Axinn managing partner 2017–2023; lead trial counsel in Cosmo Technologies v. Alvogen Pine Brook (D. Del.) (Uceris®/budesonide), where he won a Rule 52(c) judgment of non-infringement at the close of plaintiffs' case and the court later awarded Alvogen attorneys' fees under 35 U.S.C. § 285 as an "exceptional" case (Axinn client alert, Mar. 28, 2019; Fed. Cir. summarily affirmed Jan. 14, 2019). Also the Axinn relationship partner for Alvogen across multiple ANDA matters.
• Brett M. Garrison — Axinn (Washington, DC) litigator and part of the firm's Alvogen Hatch-Waxman team; appears on pro hac vice motions alongside Becker in D. Del. pharma cases (e.g., Thermo Fisher v. Agilent, Cosmo v. Alvogen).

Caveats and open items

1. No in-house counsel of record. I found no Alvogen in-house attorney appearing on the 19-310 docket. Alvogen's in-house legal leadership is not identified in any filing I could access.
2. Alvogen Luxembourg / Alvogen Lux Holdings S.à r.l. — The third named defendant in the caption appears in the March/April 2019 extension stipulations ("filed by Alvogen Lux Holdings S.a.r.l., Alvogen Malta Operations Ltd., Alvogen Pine Brook LLC," signed by Farnan) and in an earlier summons/serving declaration, but it is not named in the Consent Judgment caption, and I did not confirm any separate appearance or pro hac vice admission on its behalf. Treat its representation as unverified.
3. Pro hac vice scope. The docket reflects only Becker and Garrison admitted pro hac vice for the Alvogen defendants in 19-310. Other Axinn attorneys who routinely staff Alvogen matters (e.g., Jason T. Murata, Stacie L. Ropka, Delphine W. Knight Brown) appear in other Alvogen cases but not on this docket — I am flagging that rather than asserting they worked this case.
4. Withdrawal vs. termination. Because the case ended by consent judgment on July 16, 2020, the CM/ECF attorney entries were terminated on that date rather than withdrawn. There was no notice of withdrawal, and I found no sealed appearance records. Any sealing of counsel-related filings is not evident from the public docket, and I cannot rule it out.
5. Axinn→RLF lead designation. Farnan is coded "LEAD ATTORNEY" in CM/ECF (the Delaware-counsel field), but the substantive/first-chair role was Axinn's — that is why Becker and Garrison appear in the "OF COUNSEL" block on the answer. If you need one name for "lead defense counsel of record in this case," it is Kelly E. Farnan.